SCHEMBL9632134

SCHEMBL9632134

O=C(O)C(c1ccccc1)N1C(=O)CCC1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
ALDH1A1 P00352 3/20 0.53
PKM P14618 1/20 0.53
GAA P10253 2/20 0.51
KDM4E B2RXH2 2/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
XIAP P98170 1/20 0.49
HKDC1 Q2TB90 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TRPV1 Q8NER1 1/20 0.46
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
CYP2D6 P10635 1/20 0.43
SRC P12931 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22207807 0.85 ALDH1A1 (0.46) LMNAALDH1A1PKMGAAKDM4E
SCHEMBL22207710 0.84 ALDH1A1 (0.41) LMNAALDH1A1PKMGAAKDM4E
SCHEMBL6319092 0.84 LMNA (0.52) LMNAALDH1A1PKMGAAKDM4E
SCHEMBL4826685 0.82 CYP11B1 (0.45) ALDH1A1PKML3MBTL1SLC1A2
SCHEMBL8649993 0.79 PARL (0.45) ALDH1A1PKMGAAKDM4ETDP1
SCHEMBL4957962 0.78 LMNA (0.50) LMNAALDH1A1GAAKDM4EALOX15
SCHEMBL23886963 0.78 CYP3A4 (0.59) LMNAALDH1A1GAAKDM4EALOX15
SCHEMBL6690737 0.77 ALDH1A1 (0.57) LMNAALDH1A1GAAKDM4EALOX15
SCHEMBL6694241 0.77 ALDH1A1 (0.57) LMNAALDH1A1GAAKDM4EALOX15
SCHEMBL5866035 0.77 ALDH1A1 (0.57) LMNAALDH1A1GAAKDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109103-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES UNIWERSYTET JAGIELLONSKI (PL) 2025-04-03 US disclosed
CN-113272292-B (2, 5-dioxopyrrolidin-1-yl) (phenyl) -acetamide derivatives and their use in the treatment of neurological diseases 雅盖隆大学 2024-04-12 CN disclosed
EP-3908580-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES UNIWERSYTET JAGIELLONSKI (PL) 2021-11-17 EP disclosed
WO-2020145831-A1 (2,5-DIOXOPYRROLIDIN-L-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES Uniwersytet Jagielloński (PL) 2020-07-16 WO disclosed
US-5105007-A Fluorescence polarization immunoassay ABBOTT LABORATORIES (US) 1992-04-14 US disclosed
US-5100807-A Fluorescence polarization immunoassay ABBOTT LABORATORIES (US) 1992-03-31 US disclosed
EP-0312898-A2 Phenylacetylglutamine (pag) analytical test ABBOTT LABORATORIES (US) 1989-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109103-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES TRPV5, SCN5A, P2RX5 LMNA 2019/4885ALDH1A1 279/4885PKM 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.